Decker K, Koschinski A, Trouliaris S, Tamura T, Dreyer F, Repp H
Rudolf-Buchheim-Institut für Pharmakologie, Justus-Liebig-Universität Giessen, Germany.
Naunyn Schmiedebergs Arch Pharmacol. 1998 Apr;357(4):378-84. doi: 10.1007/pl00005182.
We investigated the effects of the receptor-coupled protein tyrosine kinase (RTK) v-Fms on the membrane current properties of NIH3T3 mouse fibroblasts. We found that v-Fms, the oncogenic variant of the macrophage colony-stimulating factor receptor c-Fms, activates a K+ current that is absent in control cells. The activation of the K+ current was Ca2+-dependent, voltage-independent, and was completely blocked by the K+ channel blockers charybdotoxin, margatoxin and iberiotoxin with IC50 values of 3 nM, 18 nM and 76 nM, respectively. To identify signalling components that mediate the activation of this K+ current, NIH3T3 cells that express different mutants of the wild-type v-Fms receptor were examined. Mutation of the binding site for the Ras-GTPase-activating protein led to a complete abolishment of the K+ current. A reduction of 76% and 63%, respectively, was observed upon mutation of either of the two binding sites for the growth factor receptor binding protein 2. Mutation of the ATP binding lobe, which disrupts the protein tyrosine kinase activity of v-Fms, led to a 55% reduction of the K+ current. Treatment of wild-type v-Fms cells with Clostiridium sordellii lethal toxin or a farnesyl protein transferase inhibitor, both known to inhibit the biological function of Ras, reduced the K+ current amplitude to 17% and 6% of the control value, respectively. This is the first report showing that an oncogenic RTK can modulate K+ channel activity. Our results indicate that this effect is dependent on the binding of certain Ras-regulating proteins to the v-Fms receptor and is not abolished by disruption of its intrinsic protein tyrosine kinase activity. Furthermore, our data suggest that Ras plays a key role for K+ channel activation by the oncogenic RTK v-Fms.
我们研究了受体偶联蛋白酪氨酸激酶(RTK)v-Fms对NIH3T3小鼠成纤维细胞膜电流特性的影响。我们发现,巨噬细胞集落刺激因子受体c-Fms的致癌变体v-Fms可激活对照细胞中不存在的钾离子电流。钾离子电流的激活依赖于钙离子,不依赖于电压,并且被钾离子通道阻滞剂蝎毒素、玛格毒素和埃博毒素完全阻断,其半数抑制浓度(IC50)值分别为3 nM、18 nM和76 nM。为了鉴定介导这种钾离子电流激活的信号成分,我们检测了表达野生型v-Fms受体不同突变体的NIH3T3细胞。Ras-GTP酶激活蛋白结合位点的突变导致钾离子电流完全消失。生长因子受体结合蛋白2的两个结合位点之一发生突变后,钾离子电流分别降低了76%和63%。ATP结合结构域的突变破坏了v-Fms的蛋白酪氨酸激酶活性,导致钾离子电流降低了55%。用已知可抑制Ras生物学功能的索氏梭菌致死毒素或法尼基蛋白转移酶抑制剂处理野生型v-Fms细胞,钾离子电流幅度分别降至对照值的17%和6%。这是首次报道致癌性RTK可调节钾离子通道活性。我们的结果表明,这种效应依赖于某些Ras调节蛋白与v-Fms受体的结合,并且不会因其内在蛋白酪氨酸激酶活性的破坏而消除。此外,我们的数据表明Ras在致癌性RTK v-Fms激活钾离子通道中起关键作用。